Skip to content
  • People
  • Pipeline
  • Publications
  • News
  • People
  • Pipeline
  • Publications
  • News
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
  • People
  • Pipeline
  • Publications
  • News
  • Contact us
Contact

News

Read all about our latest news.
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board
News Article
-
April 17, 2025

Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board

Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment
News Article
-
February 25, 2025

Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment

Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
News Article
-
January 21, 2025

Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program

Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
News Article
-
January 14, 2025

Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Press Release
-
November 26, 2024

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia

Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Press Release
-
November 19, 2024

Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program

Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Press Release
-
October 15, 2024

Monument Therapeutics Secures £1M Investment To Fund Its Schizophrenia Programme And Drive Next Stage of Growth

Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980
Press Release
-
September 17, 2024

Monument Therapeutics Announces Grant of UK Patent for Neuroinflammation Compound MT1980

Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.
Press Release
-
April 18, 2024

Precision neuroscience company Monument Therapeutics announces £1.5m funding to kickstart schizophrenia clinical development.

Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia
Press Release
-
January 4, 2024

Monument Therapeutics announces the grant of U.S. patent supporting MT1988 program for schizophrenia

Post-Covid-19 cognitive impairment: a new target for drug development?
News Article
-
April 25, 2023

Post-Covid-19 cognitive impairment: a new target for drug development?

Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference
Press Release
-
March 28, 2023

Stratified neuroscience company Monument Therapeutics to present positive data for first clinical study of MT1980, a novel treatment for neuroinflammation, at AD/PD conference

Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Press Release
-
January 9, 2023

Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives

The rise of digital biomarkers in neuroscience drug development
News Article
-
October 19, 2022

The rise of digital biomarkers in neuroscience drug development

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Press Release
-
August 2, 2022

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Press Release
-
June 13, 2022

Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation

We are attending the BIO Conference: join us at two exciting sessions
News Article
-
June 7, 2022

We are attending the BIO Conference: join us at two exciting sessions

Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
News Article
-
May 2, 2022

Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)

Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!
News Article
-
April 26, 2022

Our CSO Dr Kiri Granger is listed as one of In Vivo’s 2022 ‘Rising Leaders’!

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA
News Article
-
April 11, 2022

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference
Press Release
-
March 15, 2022

Stratified medicine company Monument Therapeutics to present positive preclinical data for anti-neuroinflammation target MT1980 at AD/PD conference

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference
Press Release
-
March 15, 2022

Stratified medicine company Monument Therapeutics to announce development of novel risk prediction tool for post-operative cognitive decline at AD/PD conference

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic
Press Release
-
December 14, 2021

Stratified medicine company Monument Therapeutics raises additional £0.5 million to take anti-neuroinflammation candidate MT1980 into clinic

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study
Press Release
-
September 21, 2021

Monument Therapeutics collaborates with the University of Nottingham on pioneering schizophrenia study

New Interview in Scrip
News Article
-
September 13, 2021

New Interview in Scrip

Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board
Press Release
-
August 12, 2021

Monument Therapeutics is delighted to announce the appointment of Dr Paula Moran to its Scientific Advisory Board

Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director
Press Release
-
August 3, 2021

Monument Therapeutics is delighted to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director

Digital brain biomarker company Monument Therapeutics raises £2.6 million
Press Release
-
July 1, 2021

Digital brain biomarker company Monument Therapeutics raises £2.6 million

Richard Bungay Joins the Board as a Director
Press Release
-
June 29, 2017

Richard Bungay Joins the Board as a Director

Bringing Precision Medicine to
Neuroscience Drug Development

MT LOGO WHITE PNG-01
info@monumenttx.com
Get in touch
© Copyright 2025  |  Privacy Policy & Terms of Use